LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.

    Rizas, Konstantinos D / Freyer, Luisa / Sappler, Nikolay / von Stülpnagel, Lukas / Spielbichler, Peter / Krasniqi, Aresa / Schreinlechner, Michael / Wenner, Felix N / Theurl, Fabian / Behroz, Amira / Eiffener, Elodie / Klemm, Mathias P / Schneidewind, Annika / Zens, Martin / Dolejsi, Theresa / Mansmann, Ulrich / Massberg, Steffen / Bauer, Axel

    Nature medicine

    2022  Volume 28, Issue 9, Page(s) 1823–1830

    Abstract: Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial ( NCT04250220 ) ...

    Abstract Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial ( NCT04250220 ), we randomly assigned 5,551 policyholders of a German health insurance company who were free of AF at baseline (age 65 years (median; interquartile range (11) years, 31% females)) to digital screening (n = 2,860) or usual care (n = 2,691). In this siteless trial, for digital screening, participants used a certified app on their own smartphones to screen for irregularities in their pulse waves. Abnormal findings were evaluated by 14-day external electrocardiogram (ECG) loop recorders. The primary endpoint was newly diagnosed AF within 6 months treated with oral anti-coagulation by an independent physician not involved in the study. After 6 months, participants were invited to cross-over for a second study phase with reverse assignment for secondary analyses. The primary endpoint of the trial was met, as digital screening more than doubled the detection rate of treatment-relevant AF in both phases of the trial, with odds ratios of 2.12 (95% confidence interval (CI), 1.19-3.76; P = 0.010) and 2.75 (95% CI, 1.42-5.34; P = 0.003) in the first and second phases, respectively. This digital screening technology provides substantial benefits in detecting AF compared to usual care and has the potential for broad applicability due to its wide availability on ordinary smartphones. Future studies are needed to test whether digital screening for AF leads to better treatment outcomes.
    MeSH term(s) Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Child ; Delivery of Health Care ; Electrocardiography ; Female ; Humans ; Male ; Mass Screening ; Smartphone
    Language English
    Publishing date 2022-08-28
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-01979-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based bavarian alternative detection of Atrial Fibrillation (eBRAVE-AF) trial.

    Freyer, Luisa / von Stülpnagel, Lukas / Spielbichler, Peter / Sappler, Nikolay / Wenner, Felix / Schreinlechner, Michael / Krasniqi, Aresa / Behroz, Amira / Eiffener, Elodie / Zens, Martin / Dolejsi, Theresa / Massberg, Steffen / Rizas, Konstantinos D / Bauer, Axel

    American heart journal

    2021  Volume 241, Page(s) 26–34

    Abstract: Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison ...

    Abstract Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison with routine symptom-based screening is unknown. eBRAVE-AF is an investigator-initiated, digital, prospective, randomized, siteless, open-label, cross-over study to evaluate an e-health-based strategy for detection of AF in a real-world setting. 67,488 policyholders of a large German health insurance company (Versicherungskammer Bayern, Germany) selected by age ≥ 50 years and a CHA
    MeSH term(s) Asymptomatic Diseases/epidemiology ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Cross-Over Studies ; Female ; Germany/epidemiology ; Humans ; Insurance, Health/statistics & numerical data ; Male ; Middle Aged ; Mobile Applications ; Monitoring, Ambulatory/instrumentation ; Monitoring, Ambulatory/methods ; Randomized Controlled Trials as Topic/methods ; Smartphone ; Telemedicine/instrumentation ; Telemedicine/methods
    Language English
    Publishing date 2021-07-09
    Publishing country United States
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 80026-0
    ISSN 1097-6744 ; 0002-8703
    ISSN (online) 1097-6744
    ISSN 0002-8703
    DOI 10.1016/j.ahj.2021.06.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top